For instance, dual targeting of CCL2/CCR2 and PD-1 has yielded notable tumor suppression and improved survival of tumor-bearing mice.367–369 These advances underscore the importance of the CCL2-CCR2 axis in cancer immunology and its potential as a therapeutic target. The gene discussed is CCL2; the disease is neoplasm.